

**Revised Draft Agenda**

*Scientific Advisory Committee on  
Alternative Toxicological Methods  
October 20, 2004*

U.S. Environmental Protection  
Agency, Building C, Room C111  
(Auditorium sections A. and B), 109  
T.W. Alexander Drive, Research  
Triangle Park, NC 27709. (A photo ID is  
required to access the EPA campus.)

8:30 a.m.

- Call to Order and Introductions
  - Welcome and Remarks from the  
National Institute of Environmental  
Health Sciences (NIEHS) and the  
National Toxicology Program (NTP)
    - Welcome and Remarks from the  
Interagency Coordinating Committee on  
the Validation of Alternative Methods  
(ICCVAM) Chair
    - Update on Activities of the National  
Toxicology Program (NTP) Interagency  
Center for the Evaluation of Alternative  
Toxicological Methods (NICEATM) and  
ICCVAM
    - Update on the European Center for  
the Validation of Alternative Methods  
(ECVAM) Workshop Recommendations  
and Validation Studies
    - Evaluation of the Under-Prediction  
Rate for the *in vivo* Rabbit Dermal  
Irritation Test
      - Public Comment
    - Preliminary Evaluation of the  
Under-Prediction Rate for the *in vivo*  
Rabbit Ocular Irritation Test
      - Public Comment
- 12 p.m.: Lunch Break (on your own, the  
EPA campus has a cafeteria)

1 p.m.

- ICCVAM Nominations
  - Public Comment
- NTP Roadmap
  - Public Comment
- ICCVAM Perspectives on Proposed  
OECD Draft guidance Document on the  
Validation and International Acceptance  
of New or Updated Test methods for  
Hazard Assessment (Guidance  
Document 34)
  - General Discussion

4:30 p.m.: Adjourn

Dated: October 8, 2004.

**Samuel Wilson,**

*Deputy Director, National Institute of  
Environmental Health Sciences.*

[FR Doc. 04-23559 Filed 10-20-04; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES****National Institutes of Health****Prospective Grant of Exclusive  
License: Human Parvovirus B19  
Vaccine**

**AGENCY:** National Institutes of Health,  
Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance  
with 35 U.S.C. 209(c)(1) and 37 CFR  
404.7(a)(1)(i), that the National  
Institutes of Health (NIH), Department  
of Health and Human Services, is  
contemplating the grant of a worldwide  
exclusive license to practice the  
inventions embodied in PCT/US89/  
04948 filed November 14, 1989, and  
National Stage filed in Australia (patent  
no. 631159), Canada (patent no.  
1284268), Israel (patent no. 92298) and  
Japan (patent no. 2755817), entitled  
“Parvovirus Capsids”; U.S. patent no.  
5,508,186, U.S. patent no. 6,132,732,  
U.S. patent no. 6,001,371, U.S. patent  
no. 5,827,647, entitled “B19 Parvovirus  
Capsids”; U.S. patent no. 5,916,563,  
U.S. patent no. 6,558,676 entitled  
“Parvovirus Capsids”; and PCT/NL90/  
00130 filed September 11, 1990, and  
National Stage filed in Europe (patent  
no. 0491824), Austria (patent no.  
122395), Denmark (patent no. 0491824),  
Germany (patent no. 69019359),  
Netherlands (patent no. 8902301), Spain  
(patent no. 2073036) and United States  
(patent nos. 6,204,044, 6,287,815 and  
6,379,885), entitled “Human Parvovirus  
B19 Proteins and Virus-like Particles,  
Their Production and Their Use in  
Diagnostic Assays and Vaccines” to  
Viral Antigens, Inc., having a place of  
business in Memphis, Tennessee. The  
patent rights in these inventions have  
been assigned or exclusively licensed to  
the United States of America.

**DATES:** Only written comments and/or  
application for a license which are  
received by the NIH Office of  
Technology Transfer on or before  
January 19, 2005, will be considered.

**ADDRESSES:** Requests for a copy of the  
patent application, inquiries, comments  
and other materials relating to the  
contemplated license should be directed  
to: Susan Ano, Office of Technology  
Transfer, National Institutes of Health,  
6011 Executive Boulevard, Suite 325,  
Rockville, MD 20852-3804; e-mail:  
[anos@od.nih.gov](mailto:anos@od.nih.gov); telephone: (301) 435-  
5515; Facsimile: (301) 402-0220.

**SUPPLEMENTARY INFORMATION:** This  
technology describes a method of  
producing non-infectious recombinant  
human parvovirus B-19 capsids

composed of viral proteins VP1 and VP2  
or VP2. The technology further relates to  
diagnostic assays utilizing the  
recombinantly produced parvovirus  
capsid proteins, or antibodies to such  
proteins. The technology also describes  
a vaccine effective against parvovirus  
B19 infection, consisting of the  
recombinant capsid proteins. Data from  
the inventors show that the  
configuration of the vaccine optimal for  
eliciting neutralizing antibodies  
comprises approximately twenty five  
percent (25%) VP1 and seventy five  
percent (75%) VP2. In another  
embodiment, the technology describes  
the use of parvovirus B19 viral capsids  
as a gene delivery system for proteins.

The prospective exclusive license will  
be royalty bearing and will comply with  
the terms and conditions of 35 U.S.C.  
209 and 37 CFR 404.7. The prospective  
exclusive license may be granted unless,  
within 90 days from the date of this  
published notice, NIH receives written  
evidence and argument that establishes  
that the grant of the license would not  
be consistent with the requirements of  
35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to  
development of vaccines for parvovirus  
B19.

The licensed territory will be  
worldwide exclusive.

Properly filed competing applications  
for a license filed in response to this  
notice will be treated as objections to  
the contemplated license. Comments  
and objections submitted in response to  
this notice will not be made available  
for public inspection, and, to the extent  
permitted by law, will not be released  
under the Freedom of Information Act,  
5 U.S.C. 552.

Dated: October 14, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development  
and Transfer, Office of Technology Transfer,  
National Institutes of Health.*

[FR Doc. 04-23561 Filed 10-20-04; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HOMELAND  
SECURITY****Directorate of Science and Technology**

[Docket No. DHS-2004-0008]

**Notice of Meeting of Homeland  
Security Science and Technology  
Advisory Committee**

**AGENCY:** Office of the Under Secretary  
for Science and Technology, DHS.

**ACTION:** Notice.

**SUMMARY:** The Homeland Security  
Science and Technology Advisory